TABLE 1.
Antimicrobial resistance genetic determinants predicted in Campylobacter jejuni HS19 isolates.
| Antibiotic class | Gene | Predicted phenotype |
Frequency (%)
|
||
| Isolate from cattle (n = 14) | Isolate from GBS patients (n = 10) | Isolate from diarrhea patients (n = 9) | |||
| Tetracyclines | tet(O) a | Tetracycline | 35.70% | 10.00% | 11.10% |
| (5/14) | (1/10) | (1/9) | |||
| tet(U) b | Tetracycline | 0.00% | 0.00% | 11.10% | |
| (14/14) | (0/10) | (1/9) | |||
| CmeABC multidrug efflux complex | CmeABC and CmeRa | Multidrug resistance | 100.00% | 100.00% | 100.00% |
| (14/14) | (10/10) | (9/9) | |||
| EfrAB efflux pump | efrB c | Multidrug resistance | 0.00% | 0.00% | 11.10% |
| (0/14) | (0/10) | (1/9) | |||
| Aminoglycosides | aac(6′)-Ii d | Dibekacin, Gentamicin, netilmicin sisomicin, tobramycin | 0.00% | 0.00% | 11.10% |
| (0/14) | (0/10) | (1/9) | |||
| β-Lactams | OXA-193, OXA-450 a | Carbapenem, cephalosporin, penam | 100.00% | 100.00% | 100.00% |
| (14/14) | (10/10) | (9/9) | |||
| mecC-type BlaZe | Blaz-like beta-lactamase | 0.00% | 0.00% | 11.10% | |
| (14/14) | (0/10) | (1/9) | |||
| Point mutations | gyrA (T86I)f | Ciprofloxacin I/R, Nalidixic acid | 62.30% | 10.00% | 22.20% |
| (9/14) | (1/10) | (2/9) | |||
atet(O), CmeABC and CmeR, OXA-193,OXA-450, gyrA (T86I): sequence coverage 99.9–00%, gene identity percentage 95.2–99.87%.
btet(U): sequence coverage 96.9%, identity percentage 77.3%.
cefrB: sequence coverage 47.7%, identity percentage 78.1%.
daac(6′)-Ii: sequence coverage 78.3%, identity percentage 99.8%.
emecC-type_BlaZ: sequence coverage 85.0%, identity percentage 67.5%.
fgyrA (T86I): mutation ACA–> ATA (T–> I); coverage 100%, identity percentage 99.9%.